Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Feehally

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
Wellcome Open Research|October 23, 2018
Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohortSuceena Alexander, George T John, Anila Korula, et al.
Lancet (London, England)|March 18, 2015
International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrologyRavindra L Mehta, Jorge Cerdá, Emmanuel A Burdmann, et al.
Plos Medicine|January 14, 2021
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility studyEtienne Macedo, Ulla Hemmila, Sanjib Kumar Sharma, et al.
Kidney International Supplements|March 10, 2020
Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysisLaura Sola, Nathan W Levin, David W Johnson, et al.
Nephron|November 21, 2015
Tonsillectomy in a European Cohort of 1,147 Patients with IgA NephropathyJohn Feehally, Rosanna Coppo, Stéphan Troyanov, et al.
JAMA|August 2, 2017
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical TrialJicheng Lv, Hong Zhang, Muh Geot Wong, et al.
American Journal of Nephrology|November 3, 2021
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline CharacteristicsMuh Geot Wong, Jicheng Lv, Michelle A Hladunewich, et al.
JAMA|May 17, 2022
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical TrialJicheng Lv, Muh Geot Wong, Michelle A Hladunewich, et al.
Kidney International Supplements|March 10, 2020
Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomesRoberto Pecoits-Filho, Ikechi G Okpechi, Jo-Ann Donner, et al.
The New England Journal of Medicine|February 18, 2011
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathyHoria C Stanescu, Mauricio Arcos-Burgos, Alan Medlar, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Wellcome Open Research|October 23, 2018
Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohortSuceena Alexander, George T John, Anila Korula, et al.
Lancet (London, England)|March 18, 2015
International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrologyRavindra L Mehta, Jorge Cerdá, Emmanuel A Burdmann, et al.
Plos Medicine|January 14, 2021
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility studyEtienne Macedo, Ulla Hemmila, Sanjib Kumar Sharma, et al.
Kidney International Supplements|March 10, 2020
Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysisLaura Sola, Nathan W Levin, David W Johnson, et al.
Nephron|November 21, 2015
Tonsillectomy in a European Cohort of 1,147 Patients with IgA NephropathyJohn Feehally, Rosanna Coppo, Stéphan Troyanov, et al.
JAMA|August 2, 2017
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical TrialJicheng Lv, Hong Zhang, Muh Geot Wong, et al.
American Journal of Nephrology|November 3, 2021
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline CharacteristicsMuh Geot Wong, Jicheng Lv, Michelle A Hladunewich, et al.
JAMA|May 17, 2022
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical TrialJicheng Lv, Muh Geot Wong, Michelle A Hladunewich, et al.
Kidney International Supplements|March 10, 2020
Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomesRoberto Pecoits-Filho, Ikechi G Okpechi, Jo-Ann Donner, et al.
The New England Journal of Medicine|February 18, 2011
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathyHoria C Stanescu, Mauricio Arcos-Burgos, Alan Medlar, et al.
Pageof 14